Gene editing using CRISPR-Cas9 for the treatment of lung cancer

https://doi.org/10.25100/cm.v47i4.2856
Tumor cells can inhibit body´s immune response by binding to proteins, such as PD-1, on the surface of T cells. CRISPR-Cas9 technology that turn off PD-1 gene reactivate the immune response.

Article Sidebar

PDF PDF (Español) HTML HTML (Español)

Published: Dec 30, 2016
Updated: 2016-12-30
Issue: Vol. 47 No. 4 (2016)
Section Editorial

Publcation metrics

2153 | 716 | 887 | 8 | 1250




 


Main Article Content

Authors

Andres Castillo Departamento de Biologia. Facultad de Ciencias Naturales y Exactas. Universidad del Valle. Cali, Colombia. Editor Asociado Revista Colombia Medica. Facultad de Salud, Universidad del Valle, Cali, Colombia
Abstract
In 2015, the journal Science chose CRISPR-Cas9 technology as the most important technological advance of science in the last years. This magazine announced the beginning of a new era of biotechnology in which it would be possible to edit, correct and modify the genetic information of any cell in a feasible, fast and cheap way; and most importantly, with high precision. Its implementation in research laboratories in basic and applied sciences could help to develop therapeutic strategies for the health area with the main objective of healing diseases with a known genetic origin, and that until now have been impossible to cure
Keywords
  • Gene
  • CRISPR-Cas9
  • Cancer
  • treatment
Author Biography

Andres Castillo, Departamento de Biologia. Facultad de Ciencias Naturales y Exactas. Universidad del Valle. Cali, Colombia. Editor Asociado Revista Colombia Medica. Facultad de Salud, Universidad del Valle, Cali, Colombia

PhD en Ciencias Biomedicas Profesor Asistente. Departamento de Biologia. Facultad de Ciencias Naturales y Exactas. Universidad del Valle. Cali, Colombia.

Editor Asociado Revista Colombia Medica. Facultad de Salud, Universidad del Valle, Cali, Colombia
References

Travis J. Breakthrough of the Year: CRISPR makes the cut. Science Magazine. 2015 http://www.sciencemag.org/news/2015/12/and-science-s-breakthrough-year

Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539:479–479. DOI: https://doi.org/10.1038/nature.2016.20988

Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A. Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of Bacteriology. 1987;169(12):5429–5433. DOI: https://doi.org/10.1128/jb.169.12.5429-5433.1987

Mojica FJ, Ferrer C, Juez G, Rodríguez-Valera F. Long stretches of short tandem repeats are present in the largest replicons of the Archaea Haloferax mediterranei and Haloferax volcanii and could be involved in replicon partitioning. Mol Microbiol. 1995;17(1):85–93. DOI: https://doi.org/10.1111/j.1365-2958.1995.mmi_17010085.x

Mojica FJ, Díez-Villaseñor C, Soria E, Juez G. Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondri. Mol Microbiol. 2000;36(1):244–246. DOI: https://doi.org/10.1046/j.1365-2958.2000.01838.x

Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol. 2005;60(2):174–1826. DOI: https://doi.org/10.1007/s00239-004-0046-3

Horvath P, Barrangou R. CRISPR/Cas, the Immune System of Bacteria and Archaea. Science. 2010;327:167–170. [PubMed] DOI: https://doi.org/10.1126/science.1179555

Marraffini LA, Sontheimer EJ. CRISPR interference RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet. 2010;11(3):181–190. DOI: https://doi.org/10.1038/nrg2749

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816–821. DOI: https://doi.org/10.1126/science.1225829

Gebler C, Lohoff M, Paszkowski-Rogacz M, Mircetic J, Chakraborty D, Camgoz A, Hamann MV. Inactivation of Cancer Mutations Utilizing CRISPR/Cas9. J Natl Cancer Inst. 2016;109(1):djw183–djw183. DOI: https://doi.org/10.1093/jnci/djw183

Cyranosky D. Chinese scientists to pioneer first human CRISPR trial. Nature. 2016;535:476–477. [PubMed] DOI: https://doi.org/10.1038/nature.2016.20302

National Academies of Sciences Engineering and Medicine . International Summit on Human Gene Editing: A Global Discussion. Washington, DC: The National Academies Press; 2016.

Hirsch F, Lévy Y, Chneiweiss H. CRISPR-Cas9 A European position on genome editing. Nature. 2017;541(7635):30. DOI: https://doi.org/10.1038/541030c

How to Cite
Castillo, A. (2016). Gene editing using CRISPR-Cas9 for the treatment of lung cancer. Colombia Medica, 47(4), 178–180. https://doi.org/10.25100/cm.v47i4.2856
Usage statistics

Downloads

Download data is not yet available.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use